Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Outlook

The global phosphoinositide 3-kinase (PI3K) inhibitors market is projected to grow at a CAGR of 4.65% over the forecast period of 2024-2032.

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Targeted therapy for small molecules uses PI3K inhibitors that are relatively new in the area of oncology treatment. The development in the field of targeted therapy and their approvals are driving the growth of the industry globally. The governments across the nations have taken various measures to cut down the cost of these drugs to help patients. Such programmes help patients receive treatment at an affordable price. Thus, the emergence of such reimbursement schemes is one of the key market developments that will fuel the growth of the phosphoinositide 3-kinase inhibitors industry over the forecast period.

Market Segmentation

A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a therapeutic drug class that works by inhibiting one or more of the 3-kinase phosphoinositide enzymes.

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market By Application

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The global phosphoinositide 3-kinase (PI3K) inhibitors industry can be broadly categorised based on its applications and regions.

  • Application
    • CLL - Chronic Lymphocytic Leukaemia
    • FL - Follicular Lymphoma
    • Others

The EMR report looks into the regional phosphoinositide 3-kinase (PI3K) inhibitors markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis

The rising prevalence of cancer around the globe has resulted in the increased demand for chemotherapy and other treatment procedures. Chemotherapy drugs play a significant role in treating cancer. Their drawbacks, however, have produced a change from conventional chemotherapy to targeted therapies. As a result, extensive ongoing research is being performed on targeted therapies such as PI3K inhibitors with demonstrated effectiveness in oncology applications. Significant R&D has contributed to tailored treatments in the dominant therapeutic category. Thus, the recent launches and approvals of targeted therapy during the forecast period will contribute to the growth of phosphoinositide 3-kinase (PI3K) inhibitors industry globally. Although the complex manufacturing process of such drugs makes them expensive, which is becoming a significant challenge for manufacturers and may hamper the industry growth over the forecast period.

Competitive Landscape

The report presents a detailed analysis of the following key players in the global phosphoinositide 3-kinase (PI3K) inhibitors market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Bayer AG
  • Gilead Sciences Inc.
  • Novartis AG
  • TG Therapeutics Inc.
  • Verastem Inc.
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Application
  • Region
Breakup by Application
  • CLL - Chronic lymphocytic leukaemia
  • FL - Follicular lymphoma
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Bayer AG
  • Gilead Sciences, Inc.
  • Novartis AG
  • TG Therapeutics, Inc.
  • Verastem, Inc.
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The global phosphoinositide 3-kinase (PI3K) inhibitors market is projected to grow at a CAGR of 4.65% between 2021 and 2026.

The major drivers of the industry, such as the rising prevalence of cancer, growing demand for targeted therapies, favourable government initiatives, and growing technological advancements, are expected to aid the market growth.

The key market trends guiding the growth of the phosphoinositide 3-kinase (PI3K) inhibitors industry include the ongoing research activities and fresh approval of targeted therapies.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

CLL (chronic lymphocytic leukaemia) and FL (follicular lymphoma) are the leading applications of phosphoinositide 3-kinase (PI3K) inhibitors in the industry.

The major players in the industry are Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc., among others.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124